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Abstract
Background: With widespread resistance to antimonials in Visceral Leishmaniasis (VL) in the Indian subcontinent,
Miltefosine (MIL) has been introduced as the first line therapy. Surveillance of MIL susceptibility in natural populations of
Leishmania donovani is vital to preserve it and support the VL elimination program.
Methodology and Principal Findings: We measured in vitro susceptibility towards MIL and paromomycin (PMM) in L.
donovani isolated from VL and PKDL, pre- and post-treatment cases, using an amastigote-macrophage model. MIL
susceptibility of post-treatment isolates from cured VL cases (n=13, mean IC506SD=2.4361.44 mM), was comparable
(p.0.05) whereas that from relapses (n=3, mean IC50=4.7261.99 mM) was significantly higher (p=0.04) to that of the pre-
treatment group (n=6, mean IC50=1.8660.75 mM). In PKDL, post-treatment isolates (n=3, mean IC50=16.1362.64 mM)
exhibited significantly lower susceptibility (p=0.03) than pre-treatment isolates (n=5, mean IC50=8.6360.94 mM). Overall,
PKDL isolates (n=8, mean IC50=11.4564.19 mM) exhibited significantly higher tolerance (p,0.0001) to MIL than VL isolates
(n=22, mean IC50=2.5861.58 mM). Point mutations in the miltefosine transporter (LdMT) and its beta subunit (LdRos3)
genes previously reported in parasites with experimentally induced MIL resistance were not present in the clinical isolates.
Further, the mRNA expression profile of these genes was comparable in the pre- and post-treatment isolates. Parasite
isolates from VL and PKDL cases were uniformly susceptible to PMM with respective mean IC50=7.0562.24 mM and
6.1861.51 mM.
Conclusion: The in vitro susceptibility of VL isolates remained unchanged at the end of MIL treatment; however, isolates
from relapsed VL and PKDL cases had lower susceptibility than the pre-treatment isolates. PKDL isolates were more tolerant
towards MIL in comparison with VL isolates. All parasite isolates were uniformly susceptible to PMM. Mutations in the LdMT
and LdRos3 genes as well as changes in the expression of these genes previously correlated with experimental resistance to
MIL could not be verified for the field isolates.
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Introduction
Visceral Leishmaniasis (VL) is a potentially fatal protozoan
infection with members of the Leishmania donovani complex as the
causative species. This poverty related disease is endemic in 70
countries with a total of 200 million people at risk and an estimated
100,000 new infections annually concerning all age groups [1,2].
More than 90% of the estimated VL cases occur in India,
Bangladesh, Nepal, Sudan and Brazil [3] with India alone sharing
almost 50% of the world’s total disease burden. Post-kala-azar
dermal leishmaniasis (PKDL) is a dermal sequel of VL that develops
in 5–15% of the cured VL patients in India and in 60% cured VL
patients in Sudan and is considered to constitute a major parasite
reservoir in these regions. In the present situation, chemotherapy is
the key strategy for VL control due to the absence of vaccines and
the limited impact of vector control [4–6]. The situation is
particularly grave in Bihar, India, where more than 60% of VL
patients do not respond to traditional first line antimonial therapy.
The use of AmphotericinB and itsliposomal formulations, although
highly effective even in antimony unresponsive patients, has
limitationsbecauseofitsrenaltoxicity,highcostsandinconvenience
due to slow I.V. based administration [7,8].
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alkylphosphocholine, has proved to be highly effective against
VL with cure rates of 94%, including cases unresponsive to
antimony [2,9]. It was therefore, proposed as the first line VL
therapy and remains the mainstay in the Kala-azar elimination
program, that aims to reduce the incidence of VL to 0.0001% in
the endemic areas of the Indian subcontinent by the year 2015
[10,11]. Efficacy of MIL has also been established for the
treatment of PKDL in India [12,13]. In absence of directly
observed therapy (DOT), widespread misuse of this self-adminis-
tered drug could contribute to the rapid emergence of MIL
resistance in the field. Moreover, phase IV trial of MIL in India
suggested doubling of the relapse and failure rate compared to
phase III trials [8,14]. Treatment failures (almost all relapses) were
recently also observed in Nepal [15]. Alarmingly, VL and PKDL
treatment failure and relapse cases have already surfaced in a
significant fraction of MIL treated patients in India (unpublished
data). Unresponsiveness to MIL has been reported for cutaneous
cases due to L. braziliensis and Leishmania (Viannia) guyanensis in
South America [16,17]. Paromomycin (PMM) is an aminoglyco-
side antibiotic exhibiting high efficacy towards VL [18]. Data from
Phase IV trials confirm the safety and efficacy of PMM to treat VL
[19].
The development and spread of drug resistance has made
surveillance of drug susceptibility a high priority. In the present
investigation, through long-term monitoring of MIL treated VL/
PKDL patients, post-treatment stage parasite isolates were
obtained either as residual parasites soon after completion of
treatment or from cases that relapsed, and were compared to a set
of pre-treatment isolates. The MIL susceptibility of these isolates
was assessed with an in vitro intracellular amastigote assay and
correlated with the clinical outcome. In addition, intrinsic
sensitivity towards PMM was evaluated in the same set of clinical
isolates in order to obtain baseline susceptibility prior to its future
use in therapy.
An impaired functioning of P-Type ATPase transporters, the
LdMT–LdRos3-dependent flippase machinery, resulting in a
significant decrease of intracellular MIL concentration was
observed in experimentally induced MIL resistant leishmanial
parasites. [20,21]. The resistant phenotype was related to the
occurrence of two missense and a nonsense point mutations in the
LdMT gene, and a nonsense mutation in the start codon of the
LdRos3 gene. In our study, we have evaluated the presence of
these mutations and the mRNA expression levels of LdMT and
LdRos3 in our set of clinical isolates to explore their role as
molecular markers for monitoring MIL susceptibility in the field.
Methods
Patients and parasites
Clinical isolates of L. donovani were prepared from splenic
aspirates of VL patients reporting to KAMRC, Muzzafarpur,
Bihar or from dermal lesions of PKDL patients reporting to
Department of Dermatology, Safdarjung Hospital (SJH), New
Delhi under the guidelines of the Ethical Committee of the
respective Institute. All patients came from zones of high
endemicity in Bihar, India. VL patients received MIL treatment
for 28 days (50 mg capsule twice) while PKDL patients received
MIL for 60 days (50 mg capsule, thrice daily). Splenic smears from
all VL patients were examined microscopically at the pre and post-
treatment stages. Patients with negative or +1 smear grade were
not treated further. However, patients with smears grading $2
[22] were treated with amphotericin B deoxycholate.
Parasites isolated before onset of treatment were assigned
XXX/0 codes. MIL treatment led to complete subsidence of VL
symptoms, interpreted as clinical cure, although residual parasites
could be cultured from splenic aspirates in a substantial number of
patients at the end of 1 month of treatment. These post-treatment
isolates were assigned with XXX/1 codes. All cases were followed
up for one year. VL and PKDL cases that relapsed after an initial
cure were treated with Amphotericin B and cured. Parasites were
isolated from each of the relapse cases at the time of reported
relapse (after four, six and seven months of MIL treatment
completion in VL and after 12, 18 and 32 months of MIL
treatment in PKDL and were designated as XXX/month in
which relapse occurred.
Parasites were routinely grown in Medium 199 (Sigma) with
10% heat-inactivated fetal bovine serum (HI FBS, Gibco, USA) at
25uC.
Species characterization
Parasite DNA, isolated using Qiagen Kit, was subjected to ITS-
1 PCR-RFLP analysis for species characterization, as described
earlier [23]. The ITS1 PCR product was digested with 1 U HaeIII
enzyme (Genei, Bangalore, India) at 37uC for 2 hours, followed by
analysis on 2% agarose gel. All isolates were characterized as L.
donovani on the basis of their RFLP pattern.
Drug susceptibility assay at intracellular amastigote stage
The drug susceptibility of L. donovani parasites was assessed as
intracellular amastigotes, as previously described [24]. Briefly,
J774A.1 cells (1610
5 cells/ml) were infected with stationary phase
promastigotes at ratio of 10 : 1 (parasite : macrophage), plated into
16 well chambered Labtek tissue culture slides and incubated for
4 h at 37uCi n5 %C O 2. Excess, non-adhered promastigotes were
removed by washing and macrophages incubated for 18–24 h.
Infected cells were re-incubated for 48 h, with MIL (1, 5, 10, 20
and 30 mM) (Paladin) or PMM (1, 5, 10, 20, 30 and 40 mM)
(Gland Pharma). Macrophages were then examined for intracel-
lular amastigotes after staining with Diff-Quik solutions. The
number of L. donovani amastigotes was counted in 100 macro-
phages, at 1006 magnification. The survival rate of parasites
Author Summary
Resistance to antimonials has emerged as a major hurdle
to the treatment and control of VL and led to the
introduction of Miltefosine as first line treatment in the
Indian subcontinent. MIL is an oral drug with a long half-
life, and it is feared that resistance may emerge rapidly,
threatening control efforts under the VL elimination
program. There is an urgent need for monitoring treat-
ment efficacy and emergence of drug resistance in the
field. In a set of VL/PKDL cases recruited for MIL treatment,
we observed comparable drug susceptibility in pre- and
post-treatment isolates from cured VL patients while MIL
susceptibility was significantly reduced in isolates from VL
relapse and PKDL cases. The PKDL isolates showed higher
tolerance to MIL as compared to VL isolates. Both VL and
PKDL isolates were uniformly susceptible to PMM. MIL
transporter genes LdMT/LdRos3 were previously reported
as potential resistance markers in strains in which MIL
resistance was experimentally induced. The point muta-
tions and the down-regulated expression of these trans-
porters observed in vitro could, however, not be verified in
natural populations of parasites. LdMT/LdRos3 genes
therefore, do not appear to be suitable markers so far
for monitoring drug susceptibility in clinical leishmanial
isolates.
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determined by sigmoid regression analysis. The assays were
performed in duplicate and repeated at least twice.
Partial sequencing of LdMT and LdRos3 genes
Fourteen parasite isolates were tested for the presence of
previously described point mutations in the LdMT gene, at
positions T421N, L856P and W210*, and the LdRos3 gene, at
position M1*(Figure S1) [20,21]. Primers were designed targeting
these mutations and their adjacent regions using Primer 3 software
[25]. PCR reactions were performed with 35 ng of genomic DNA
in a 50 ml reaction volume containing 106 PCR buffer (incl.
15 mM MgCl2), 5 U/mlo fTaq polymerase (Roche), 2.5 mM
dNTPs (NEB), and 10 mM of each of the locus specific primers
(Table S1). Thermocycling conditions were as follows: initial
denaturation at 95uC for 5 min, followed by 35 cycles of
denaturation at 95uC for 30 sec, annealing with the specific
primer pair at the specific TAuC for 30 sec and extension at 72uC
for 1 min, and a final extension step at 72uC for 6 min. PCR
products with fragment sizes between 149 and 277 bp were
purified (QIAamp DNA Mini Kit, Qiagen) and sent for
commercial sequencing using forward and reverse primers (SMB
Services in Molecular Biology, Berlin Germany). Sequences were
checked, trimmed and aligned using Chromas Pro v 1.32 [26].
RNA extraction and real-time PCR analysis
Total RNA (5 mg), isolated from stationary phase promastigotes
at day six using Trizol Reagent (Invitrogen, USA) was reverse
transcribed at 42uC with M-MLV Reverse transcriptase (Invitro-
gen, USA) after deoxyribonuclease I treatment. All real-time PCR
reactions were performed in duplicate in 25 ml volumes using
SYBR Green as described before [27]. The 2
2DDCT method was
used to calculate relative changes in gene expression determined
from real-time quantitative PCR experiments. The data was
presented as the fold change in the target gene expression in
L.donovani parasites normalized to the internal control gene
(GAPDH) and relative to the LdAG83 reference strain of L.
donovani.
Ethical statement
The study was approved by the Ethical Committee of the
Institute of Medical Sciences, Banaras Hindu University, Varanasi
and Safdarjung Hospital, New Delhi, India. Written informed
consent was obtained from patients and from guardians in case of
children ,18 years.
Results
In vitro susceptibility to MIL
MIL susceptibility was determined at intracellular amastigote
stage for thirty clinical isolates, including eleven pre-treatment
isolates (six from VL and five from PKDL cases), thirteen post-
treatment isolates (obtained at the end of treatment from VL
patients which depicted a clinical cure, although parasitology was
still positive) and six relapse isolates (three VL and three PKDL).
The clinical profile of patients and in vitro susceptibility of the
isolates to MIL are summarized in Table 1.
The six VL pre-treatment isolates showed a sensitivity range of
0.9560.06 to 2.9160.24 mM towards MIL with the mean
IC506SD being 1.8660.75 mM (Figure 1). The post-treatment
VL isolates had a mean IC50 of 2.4361.44 mM (range 1.0260.17
to 5.2060.80 mM) which was not significantly different in
comparison with the pre-treatment group (p.0.05). The mean
IC50 of the three VL isolates from relapse cases (4.7261.99 mM)
was significantly higher (p=0.04) than that of pre-treatment VL
cases (1.8660.75 mM).
The three PKDL relapse isolates showed a significantly higher
(p=0.03), mean IC50 of 16.1362.64 mM in comparison with the
pre-treatment PKDL isolates (mean IC50=8.6360.94 mM). The
mean susceptibility of all VL isolates (2.5861.58 mM, n=22)
when compared with PKDL isolates (11.4564.19 mM, n=8)
revealed that the latter were significantly (p,0.0001) more tolerant
to MIL (Figure 1).
Natural susceptibility of L. donovani isolates to PMM
We evaluated PMM susceptibility of 22 VL isolates, of which 16
were exposed to MIL treatment. The IC50 ranged from 3.4160.29
to 10.7061.12 mM with mean IC50=7.0562.24 mM (Table 1).
Furthermore, the PMM sensitivity was similar (p.0.05) in
parasites non-exposed (mean IC50=7.7362.25 mM) or exposed
(mean IC50=6.7962.25 mM) to MIL (Figure 2).
The inherent PMM susceptibility of 8 PKDL isolates ranged
from 4.9260.34 to 8.6261.82 mM (Table 1). Like in VL, the
PMM IC50 of PKDL isolates was similar (p.0.05) in parasites
non-exposed (n=5, mean IC50=6.1261.40 mM) or exposed
(n=3, mean IC50=6.2962.02 mM) to MIL (Figure 2). There
was no correlation observed between MIL and PMM susceptibility
in VL (r=0.10) or PKDL isolates (r=20.02).
Point mutations in the LdMT and LdRos3 genes possibly
related to MIL resistance
None of the four reported SNPs in the LdMT and LdRos3
genes, which were suggested to be responsible for the resistant
phenotype in a strain from Ethiopia, MHOM/ET/1967/
HU3_MIL-R, with experimentally induced MIL resistance [21],
could be detected in the clinical isolates investigated (Figure S1).
Furthermore, no SNPs were detected when the three LdMT and
the LdRos3 gene fragments were sequenced in 15 clinical isolates
from Nepalese VL cases that relapsed after MIL treatment (data
not shown). Notably, the LdRos3 gene fragment could not be
amplified for the strains BHU800/1 and BHU1062/4 although no
sequence polymorphisms were identified in the primer annealing
sites.
Expression of markers of experimental MIL resistance in
field isolates
mRNA expression level of LdMT and LdRos3 was analyzed in
19 VL and two PKDL isolates using real-time PCR in comparison
to the reference strain L. donovani LdAG83. The expression was
found comparable in all the groups including the relapse cases of
VL and PKDL (Figure 3).
Discussion
The introduction of MIL therapy as treatment for VL has
pioneered the era of effective oral therapy for this potentially fatal
disease. However, anthroponotic VL transmission in the Indian
subcontinent and the long half life of MIL (150–200 h) poses the
risk of development of resistance in natural population of parasites.
It has been reported earlier that MIL resistant parasites can be
easily generated in vitro [28]. The present study reveals for the first
time, the intrinsic in vitro sensitivity of Indian L. donovani isolates
from a set of VL and PKDL patients treated with MIL (including
both responders and relapse cases). The data provides information
on the extent of MIL-tolerance in natural populations following
MIL treatment highlighting the need for adequate monitoring of
drug susceptibility to preserve this valuable drug.
Drug Sensitivity of MIL Treated VL/PKDL Isolates
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isolates was similar to the L. donovani parasites from the era of pre-
MIL treatment reported earlier [27]. At the end of MIL treatment
all cases showed clinical cure although some of them were
parasitologically positive and residual parasites could be cultured
from splenic aspirates of such patients (Table 1). The drug
susceptibility of L. donovani parasites isolated at the end of therapy
was comparable to that of pre-treatment isolates. On the contrary,
parasites obtained from the cases that relapsed exhibited
significantly reduced susceptibility to MIL, although the IC50
values were below the expected serum threshold levels [29],
implicating the possible involvement of host factors in rendering
tolerance to drug. Indeed, reports on VL relapse in HIV co-
infected patients treated with MIL suggest that host immunity
plays a role in the elimination of parasites from VL patients
[30,31]. A small number of MIL treated cases showed relapse,
parasite isolates from these were monitored for in vitro drug
susceptibility. Although we did not find any clinically resistant
strains, the observation of strains with higher MIL tolerance (up to
eight times compared to the sensitive ones) emphasizes the need
for close monitoring of cases under MIL treatment. The study also
investigated for the first time, the intrinsic susceptibility of PKDL
Table 1. Drug susceptibility of Leishmania donovani clinical isolates following Miltefosine treatment in cases of Visceral
Leishmaniasis and Post kala-azar dermal Leishmaniasis.
WHO code
1 Research code
2 Patient age/sex
Clinical response
to treatment MIL PMM
IC50±SD (mM) IC50±SD (mM)
MHOM/IN/2010/BHU782/0 V782/0 18/M Cure 0.9560.06 5.34+1.12
MHOM/IN/2010/BHU869/0 V869/0 10/F Cure 1.0560.08 8.9760.25
MHOM/IN/2010/BHU994/0 V994/0 60/M Cure 1.9660.50 9.0760.15
MHOM/IN/2010/BHU828/0 V828/0 10/M Cure 1.9860.66 5.0660.37
MHOM/IN/2010/BHU902/0 V902/0 7/M Cure 2.3060.36 10.7061.12
MHOM/IN/2009/BHU815/0 V815/0 12/F Cure 2.9160.24 7.2560.55
MHOM/IN/2010/BHU796/1 V796/1 NA Cure 1.0260.17 5.5560.89
MHOM/IN/2010/BHU1121/1 V1121/1 12/M Cure 1.1460.11 6.0560.65
MHOM/IN/2010/BHU807/1 V807/1 12/F Cure 1.2660.15 9.0860.65
MHOM/IN/2010/BHU869/1 V869/1 10/F Cure 1.3260.26 3.9160.03
MHOM/IN/2010/BHU1042/1 V1042/1 6/M Cure 1.4260.06 4.2360.76
MHOM/IN/2009/BHU815/1 V815/1 12/F Cure 2.2760.49 5.8860.64
MHOM/IN/2009/BHU741/1 V741/1 NA Cure 2.3560.40 6.0761.02
MHOM/IN/2009/BHU800/1 V800/1 35/M Cure 2.4860.04 9.8060.61
MHOM/IN/2010/BHU902/1 V902/1 7/M Cure 3.3760.38 9.2860.40
MHOM/IN/2010/BHU1093/1 V1093/1 20/M Cure 3.5760.35 3.4160.29
MHOM/IN/2009/BHU994/1 V994/1 60/M Cure 3.7260.52 5.1060.65
MHOM/IN/2010/BHU1080/1 V1080/1 12/M Cure 4.9560.28 5.8060.84
MHOM/IN/2010/BHU814/1 V814/1 NA Cure 5.2060.80 9.2060.75
MHOM/IN/2010/BHU1113/7 V1113/7 35/M Relapse 2.6760.51 7.0260.86
MHOM/IN/2010/BHU872/6 V872/6 18/M Relapse 4.8460.39 10.7061.02
MHOM/IN/2009/BHU1062/4 V1062/4 7/F Relapse 6.6660.62 7.64+0.76
MHOM/IN/1998/NIPP44/0 P44/0 18/M Cure* 7.3760.07 5.0160.38
MHOM/IN/2011/NIPP232/0 P232/0 42/M Cure 7.9960.15 8.4660.77
MHOM/IN/1998/NIPP48/0 P48/0 15/M Cure* 8.8860.18 5.8060.85
MHOM/IN/1998/NIPP49/0 P49/0 23/M Cure* 9.2360.22 5.1060.37
MHOM/IN/2001/NIPP93/0 P93/0 25/M Cure* 9.6960.52 6.2160.37
MHOM/IN/2010/NIPP195/12 P195/12 21/M Relapse 13.2660.89 8.6261.82
MHOM/IN/2010/NIPP214/18 P214/18 35/M Relapse 16.7060.65 4.9260.34
MHOM/IN/2011/NIPP214/32 P214/32 36/M Relapse 18.4560.79 5.3460.75
1WHO code: country and year of isolation and the respective strain code, the number following the isolate ID indicates the number of months elapsed after start of MIL
treatment.
2Research code: Parasites cultured from VL patients were labeled V- and from PKDL patients P-, respectively. The number following the isolate ID indicates the number
of months elapsed after start of MIL treatment (e.g. V902/1 means one month passed from first MIL treatment). Parasites isolated from patients’ prior start of MIL
treatment were labeled as XXX/0 and one month following first treatment was labeled XXX/1. These patients cleared from VL symptoms after respective duration of MIL
treatment and were interpreted as clinical cure, although residual parasites could be cultured from splenic aspirates (marked XXX/1). In the period of 1 year follow up,
cases of relapse were observed in three VL patients that had shown an initial clinical cure, the isolates obtained were designated as XXX/month in which relapse
occurred.
Cure*- Patients treated with SAG (1000 mg intra muscularly), daily for four months.
doi:10.1371/journal.pntd.0001657.t001
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was significantly higher in pre-treatment isolates than in isolates
originating from relapse patients, which were exposed to MIL for
long duration (over two months). The IC50 of PKDL isolates was
significantly higher (,4 fold) compared to VL isolates, a trend
similar to that reported earlier for SAG susceptibility in isolates
from high endemic regions [32]. This reduced drug susceptibility
of PKDL isolates may be due to longer treatment regime in PKDL
and prolonged exposure of parasites to the drug. PMM exhibited
similar in vitro susceptibility in pre- and post-treatment isolates
suggesting its potential in future VL and PKDL therapy.
The inactivation of the genes essential for MIL uptake has been
proposed as the simplest mechanism of resistance towards the drug
and L. donovani MIL transporter LdMT and its subunit LdRos3
have been reported as markers of experimental MIL resistance
[28]. Experimentally induced MIL resistant L.donovani showed
down regulated expression of these transporters [27].
In the current study, a selection of strains from Indian L. donovani
with variable response to MIL treatment has been tested for four
point mutations that were suggested to underlie the development
of MIL resistance. No nucleotide exchanges were however,
detected in the LdMT and LdRos3 gene fragments sequenced
for the set of clinical isolates studied herein, or for clinical isolates
from Nepalese MIL relapse cases (data not shown). Screening of
whole-genome data revealed that both genes are highly conserved
for the examined strains of L. donovani from the North of the Indian
subcontinent, regardless whether they were isolated from cases
responding or not responding to MIL treatment [33]. Comparison
of the expression of LdMT and LdRos3 genes revealed a similar
expression profile in the different groups of isolates studied herein.
Further studies in truly resistant parasites from MIL treated cases,
when available, are necessary to explore the possible utility of these
genes as markers for monitoring drug susceptibility in clinical
isolates. In conclusion, the causative forces leading to MIL
resistance cannot be explained by the genomic data available up to
date and it is very likely that multi-factorial events may be
responsible for the tolerance to chemotherapeutics in L. donovani
[33].
The study employed an amastigote-macrophage model for
monitoring drug susceptibility towards MIL as this stage mimics
the host milieu. However, amastigote assays are tedious, time
consuming and technically demanding. Hence, drug sensitivity
assays based on promastigotes, if found relevant, would be better
as simplified biological tool that can be used in clinical settings.
The current data recommends for keeping miltefosine susceptibil-
ity under close surveillance in the field. The risk of relapse after
MIL therapy presses the need for maintenance regimen such as
DOT for this oral drug and exploring new drug combinations for
regions endemic for VL. Regional policies concerning judicious
use of the drug and monitoring the treatment outcome should be
implemented and supervised by the health authorities in the
endemic areas to minimize the risk of emergence of MIL resistant
strains. The development of markers to identify drug unrespon-
siveness at an early stage constitutes an essential step towards the
elimination of this poverty driven disease.
Figure 1. In vitro miltefosine susceptibility of parasite isolates
from VL and PKDL cases before and after Mil treatment.
Sensitivity of VL and PKDL isolates at intracellular amastigote stage
were determined by infection in murine macrophage cell line J774A.1.
Each individual value represents mean IC506SD of the results from two
separate assays.
doi:10.1371/journal.pntd.0001657.g001
Figure 2. PMM susceptibility profile of VL and PKDL isolates
exposed or non-exposed to MIL treatment. Susceptibility of VL
and PKDL isolates at intracellular amastigote stage was determined by
infection in murine macrophage cell line J774A.1. Each individual value
represents mean IC506SD of the results from two separate assays.
doi:10.1371/journal.pntd.0001657.g002
Figure 3. Expression of LdMT and LdRos3 in clinical isolates of
VL and PKDL. Real-time reverse-transcription PCR expression analysis
of L. donovani MIL transporter genes (LdMT and LdRos3) was performed
using GAPDH as internal control. Graph shows the expression index,
defined as ratio of gene expression relative to that of strain LdAG83.
Data represent the mean6SD of the results of three independent
experiments.
doi:10.1371/journal.pntd.0001657.g003
Drug Sensitivity of MIL Treated VL/PKDL Isolates
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Figure S1 Alignments of sequences for four mutations in
the MIL transporter genes potentially linked to in vitro
resistance. The wild-type of the reference strain (MHOM/ET/
1967/HU3) is represented in blue color and the reference strain
(MHOM/ET/1967/HU3_M) in which miltefosine resistance was
experimentally induced in red color. Identified point mutations are
labelled in green for verified SNPs previously described. Additional
point mutations are marked yellow. Note that BHU902/1 and
BHU800/1 could not be amplified with primers designed for locus
LdRos3. A) Alignment for locus G630A in the putative Leishmania
donovani miltefosine transporter. B) Alignment for locus G1261T in
the putative Leishmania donovani miltefosine transporter. C) Align-
ment for locus T2567C in the putative Leishmania donovani
miltefosine transporter. D) Alignment for locus G3T in the putative
Leishmania donovani miltefosine transporter beta subunit (LdRos3).
(DOC)
Table S1 Primer sets employed to test for the point
mutations of interest.
(DOCX)
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